Variablea | Study Timeline | L-carnitine (n = 30), mean ± SD) | Placebo (n = 30), mean ± SD | p-value2 | p-value3 | p-value4 | |
---|---|---|---|---|---|---|---|
Inflammation status | CRP (mg/dl) | Baseline | 77.20 ± 28.23 | 63.50 ± 36.60 | 0.110 | 0.001 | 0.001 |
Endpoint | 54.43 ± 29.11 | 64.51 ± 29.20 |  | ||||
Mean difference ± SD | -22.77 ± 25.40 | 1.02 ± 21.10 |  | ||||
p-value1 |  < 0.001 | 0.794 |  |  |  | ||
ESR (mm/hr) | Baseline | 72.37 ± 23.99 | 53.47 ± 29.43 | 0.008 | 0.151 | 0.151 | |
Endpoint | 60.19 ± 25.37 | 54.14 ± 32.71 |  | ||||
Mean difference ± SD | -12.18 ± 21.16 | 0.67 ± 22.43 |  | ||||
p-value | 0.004 | 0.871 | Â | Â | Â | ||
Oxidative stress status | TAC (nmol/ml) | Baseline | 4.23 ± 1.09 | 4.14 ± 0.96 | 0.679 | 0.821 | 0.835 |
Endpoint | 5.06 ± 1.40 | 5.04 ± 0.95 |  | ||||
Mean difference ± SD | 0.83 ± 1.95 | 0.90 ± 1.37 |  | ||||
p-value |  < 0.001 |  < 0.001 |  |  |  | ||
MDA (nmol/ml) | Baseline | 32.21 ± 6.19 | 32.10 ± 7.33 | 0.829 | 0.814 | 0.879 | |
Endpoint | 32.78 ± 6.55 | 32.39 ± 6.13 |  | ||||
Mean difference ± SD | 0.58 ± 4.05 | 0.29 ± 2.82 |  | ||||
p-value | 0.501 | 0.215 | Â | Â | Â | ||
SOD activity (U/ml) | Baseline | 18.02 ± 13.34 | 20.75 ± 15.59 | 0.402 | 0.071 | 0.050 | |
Endpoint | 23.25 ± 11.96 | 19.17 ± 10.05 |  | ||||
Mean difference ± SD | 5.23 ± 11.97 | -1.58 ± 17.32 |  | ||||
p-value |  < 0.001 |  < 0.001 |  |  |  |